Literature DB >> 29517223

Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.

Chia-Ping Huang Yang1,2, Changwei Wang3, Iwao Ojima3, Susan Band Horwitz1.   

Abstract

Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing βIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance. Using a photoaffinity Taxol analogue, 2-( m-azidobenzoyl)taxol, two potent next-generation taxanes, SB-T-1214 and SB-CST-10202, exhibited distinct inhibitory effects on photolabeling of β-tubulin from different eukaryotic sources that differ in β-tubulin isotype composition. They also specifically inhibited photolabeling of P-gp, and the inhibitory effect correlated well with the steady-state accumulation of [3H]vinblastine in a multidrug resistant (MDR) cell line, SKVLB1. Several microtubule-stabilizing agents (MSAs)-resistant cell lines from the human ovarian cancer cell line Hey were isolated, and their MDR1 and βIII-tubulin levels determined. Distinct potencies of the two taxanes against different MSA-resistant cells expressing unique levels of MDR1 and βIII-tubulin were found. Cytotoxicity assays, done in the presence of verapamil, indicated that SB-T-1214 is a substrate, although not as good as Taxol, for P-gp. The mechanisms involved in drug resistance are multifactorial, and the effectiveness of new Taxol analogues depends on the interaction between the drugs and all possible targets; in this case the two major cellular targets are β-tubulin and P-gp.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29517223      PMCID: PMC6147140          DOI: 10.1021/acs.jnatprod.7b01047

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  25 in total

Review 1.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

2.  Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.

Authors:  Antonella Pepe; Liang Sun; Ilaria Zanardi; Xinyuan Wu; Cristiano Ferlini; Gabriele Fontana; Ezio Bombardelli; Iwao Ojima
Journal:  Bioorg Med Chem Lett       Date:  2009-04-22       Impact factor: 2.823

Review 3.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

4.  Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.

Authors:  Jakob Albrethsen; Ruth H Angeletti; Susan Band Horwitz; Chia-Ping Huang Yang
Journal:  Mol Cancer Ther       Date:  2013-11-19       Impact factor: 6.261

5.  Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.

Authors:  Yaqing Wang; Shanghua Yin; Kristie Blade; George Cooper; Donald R Menick; Fernando Cabral
Journal:  Biochemistry       Date:  2006-01-10       Impact factor: 3.162

6.  Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol.

Authors:  S Rao; L He; S Chakravarty; I Ojima; G A Orr; S B Horwitz
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

Authors:  I Ojima; J C Slater; E Michaud; S D Kuduk; P Y Bounaud; P Vrignaud; M C Bissery; J M Veith; P Pera; R J Bernacki
Journal:  J Med Chem       Date:  1996-09-27       Impact factor: 7.446

9.  Design, synthesis, and biological evaluation of new-generation taxoids.

Authors:  Iwao Ojima; Jin Chen; Liang Sun; Christopher P Borella; Tao Wang; Michael L Miller; Songnian Lin; Xudong Geng; Larisa Kuznetsova; Chuanxing Qu; David Gallager; Xianrui Zhao; Ilaria Zanardi; Shujun Xia; Susan B Horwitz; Jon Mallen-St Clair; Jennifer L Guerriero; Dafna Bar-Sagi; Jean M Veith; Paula Pera; Ralph J Bernacki
Journal:  J Med Chem       Date:  2008-05-09       Impact factor: 7.446

10.  Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin.

Authors:  S Rao; G A Orr; A G Chaudhary; D G Kingston; S B Horwitz
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

View more
  4 in total

1.  Structural Refinement of the Tubulin Ligand (+)-Discodermolide to Attenuate Chemotherapy-Mediated Senescence.

Authors:  Boying Guo; Alicia Rodriguez-Gabin; Andrea E Prota; Tobias Mühlethaler; Nan Zhang; Kenny Ye; Michel O Steinmetz; Susan Band Horwitz; Amos B Smith; Hayley M McDaid
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

Review 2.  Utilization of Photoaffinity Labeling to Investigate Binding of Microtubule Stabilizing Agents to P-Glycoprotein and β-Tubulin.

Authors:  Chia-Ping Huang Yang; Susan Band Horwitz; Hayley M McDaid
Journal:  J Nat Prod       Date:  2022-03-03       Impact factor: 4.803

3.  Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo.

Authors:  Yu Wei Deng; Wen Jing Hao; Yi Wen Li; Yi Xin Li; Bo Chen Zhao; Dan Lu
Journal:  J Breast Cancer       Date:  2018-09-12       Impact factor: 3.588

4.  CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer.

Authors:  Hailing Duan; Zaixing Yang; Lan Liang; Xiangdong Zhou
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.